Two Sigma Investments LP Reduces Stock Holdings in Qiagen (NYSE:QGEN)

Two Sigma Investments LP lowered its position in shares of Qiagen (NYSE:QGEN) by 24.1% during the fourth quarter, Holdings Channel reports. The firm owned 940,394 shares of the company’s stock after selling 298,001 shares during the quarter. Two Sigma Investments LP’s holdings in Qiagen were worth $41,876,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in QGEN. Tidal Investments LLC increased its position in Qiagen by 72.7% in the 4th quarter. Tidal Investments LLC now owns 18,559 shares of the company’s stock valued at $826,000 after acquiring an additional 7,815 shares during the period. Teza Capital Management LLC raised its holdings in Qiagen by 30.4% during the fourth quarter. Teza Capital Management LLC now owns 28,991 shares of the company’s stock worth $1,291,000 after purchasing an additional 6,766 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Qiagen by 170.6% during the 4th quarter. Point72 Asset Management L.P. now owns 125,646 shares of the company’s stock worth $5,595,000 after buying an additional 79,207 shares during the last quarter. Quantinno Capital Management LP raised its position in Qiagen by 45.8% during the fourth quarter. Quantinno Capital Management LP now owns 114,774 shares of the company’s stock worth $5,114,000 after acquiring an additional 36,067 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its stake in Qiagen by 31.6% in the 4th quarter. Parkman Healthcare Partners LLC now owns 277,272 shares of the company’s stock valued at $12,347,000 after buying an additional 66,503 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Down 0.2%

NYSE:QGEN opened at $42.72 on Wednesday. Qiagen has a one year low of $37.63 and a one year high of $49.30. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The company has a market capitalization of $9.50 billion, a price-to-earnings ratio of 118.95, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. The stock has a 50-day simple moving average of $41.11 and a 200 day simple moving average of $41.83.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. The business had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.44 EPS. Sell-side analysts predict that Qiagen will post 2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

QGEN has been the topic of a number of recent research reports. Redburn Atlantic lowered shares of Qiagen from a “buy” rating to a “neutral” rating in a report on Friday, April 4th. Baird R W cut Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. StockNews.com raised shares of Qiagen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 15th. UBS Group decreased their target price on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Robert W. Baird lifted their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Seven analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $48.42.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.